5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effe

Trial Details

NCT ID
NCT04610372
Phase
NA
Sponsor
British Columbia Cancer Agency
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Hypofractionated external beam radiotherapy
  • High dose rate brachytherapy
  • Permanent seed implant
  • Stereotactic body radiotherapy
Locations (sample)
  • Kelowna, British Columbia, Canada|49.88307,-119.48568
  • Surrey, British Columbia, Canada|49.10635,-122.82509
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Victoria, British Columbia, Canada|48.4359,-123.35155

Key Eligibility Criteria

  • Signed study specific informed consent
  • European Cooperative Oncology Group performance status 0 to 2
  • Histologically confirmed adenocarcinoma of the prostate
  • Any Tumor stage, any T, any N, M1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →